Our world has certainly changed in 2020. Not just our myeloma world, but the entire world has been affected by the SARS-CoV2 pandemic. There is good news for both challenges. There were 688 myeloma abstracts at ASH 2020 (179 orals / 500 posters / 9 publications). While this was less than in years past, it is still much […]
Michael Tuohy
Michael Tuohy was diagnosed with multiple myeloma in 2000 when he was 36 years old. With two young children (ages 2 and 7) the focus was always on finding the best treatment options, and beating myeloma. He had an autologous stem cell transplant in 2002, and is currently on Revlimid® His approach over the years has been to become empowered by learning as much as he could to have productive conversations with his doctors, and to then share his experience with others to help them along their own journey. He and his wife Robin started the first myeloma support group in Connecticut in the Spring of 2001 with the help of the IMF, which is known as the Connecticut Multiple Myeloma Fighters Information Group.
Follow Michael on Twitter
Continuing to “Take A Bite” Out of Myeloma 2020
Last year, in one of my ASH19 blogs, I wrote about bi-specific T cell engager (BiTE) therapy. BiTEs excite me the most of the newer therapies in clinical trials. They harness the power of the immune system and are off-the-shelf, unlike CAR T where your T cells are harvested, then re-engineered, then given back to you […]
“The Show Must Go On”: This Pandemic Can’t Stop the IMF
Friday, the International Myeloma Foundation held its annual symposium at #ASH20. This has always been a highlight for me as it’s a primer of what’s to come with all the abstracts throughout the weekend. This CME-certified webinar featuring discussion of patient-case studies and key clinical trial data by renowned clinical experts providing their perspectives on […]
Virtual ASH 2020: Don’t Stand So Close To Me
It’s the year 2020 which is a notable year for reasons beside being a global pandemic. For me, 2020 marks my 20th year of survival with multiple myeloma. I am deeply grateful for all the research that has taken place and hopeful for the future of myeloma, all while waiting for a cure. In 2000, […]